Vitiligo Treatment Has Changed: Understanding Today’s Options

Vitiligo is easy to recognize by its loss of pigment, but what is happening beneath the surface is considerably more complex.

The condition develops when melanocytes, the cells responsible for producing melanin, are lost from affected skin. Current evidence points strongly toward an immune-mediated process in which melanocyte-specific immune responses contribute to their destruction. Researchers have also identified important roles for oxidative stress, genetic susceptibility, interferon-gamma signaling, and the JAK-STAT pathway.

That understanding has changed the way dermatologists think about vitiligo. Treatment is no longer simply about trying to “bring the color back.” A dermatologist may be considering two separate goals: controlling active disease so that new areas of depigmentation stop appearing, and encouraging repigmentation in skin that has already lost color.

Those goals may require different approaches, and the treatment that makes sense for one person may not be the right choice for another.

What Is Actually Happening in Vitiligo?

Melanin gives skin much of its color, and melanocytes are the specialized cells that produce it. In vitiligo, affected areas lose functional melanocytes, resulting in sharply defined areas of depigmented skin.

Vitiligo is generally considered an autoimmune disease, although its biology involves several interconnected mechanisms. One pathway receiving considerable attention is the interferon-gamma (IFN-γ)/JAK-STAT signaling pathway. IFN-γ and related chemokines such as CXCL9 and CXCL10 participate in recruiting immune cells toward melanocytes, helping sustain the inflammatory process associated with vitiligo.

This matters clinically because understanding the signaling pathways involved in melanocyte destruction has opened the door to therapies that target specific components of the immune response.

It also helps explain why vitiligo is more than a cosmetic change in pigmentation. It is a biologically active skin disease.

Not All Vitiligo Behaves the Same Way

One of the first distinctions a dermatologist may make is whether vitiligo is segmental or nonsegmental.

Nonsegmental vitiligo is the more common form and often develops on both sides of the body in a relatively symmetrical distribution. Segmental vitiligo tends to affect one region or one side of the body and frequently follows a different clinical course. Vitiligo can also be categorized further according to its distribution and extent.

Another important question is whether the disease is stable or active.

Someone developing new patches or noticing existing patches expanding may need a different strategy from someone whose vitiligo has remained unchanged for a long period. For active disease, slowing or stopping progression can become an immediate treatment goal. For stable disease, the emphasis may shift more heavily toward repigmentation.

That distinction is one reason there is no single “best treatment for vitiligo.”

Not Every White Patch Is Vitiligo

A lighter area of skin does not automatically mean vitiligo.

Dermatologists may consider other causes of hypopigmentation or depigmentation based on the appearance and location of the patches, the patient's history, associated symptoms, and how the areas have changed over time.

Vitiligo can often be diagnosed clinically. In some situations, a Wood's lamp examination may help a dermatologist evaluate pigment loss more clearly, particularly when the difference between affected and unaffected skin is subtle. Additional testing may be considered when the diagnosis or an associated condition is uncertain.

Establishing the diagnosis matters before treatment begins because therapies intended to suppress inflammation or encourage repigmentation will not necessarily address every condition that produces lighter skin.

Treatment Starts With the Location, Activity, and Extent of Disease

Two people can both have vitiligo and leave a dermatology visit with very different treatment plans.

A dermatologist may consider how much skin is involved, whether new areas are appearing, how quickly the disease is changing, where the patches are located, the patient's age, previous treatments, and the potential risks and benefits of different therapies.

Location is particularly important because not every area of the body repigments equally well. The face and neck generally respond better to treatment, while areas such as the fingertips and toes tend to be considerably more resistant.

That difference has a biological explanation. Repigmentation frequently involves melanocyte reservoirs associated with hair follicles, so areas with fewer or no hair follicles can be more difficult to repigment.

It also means that treatment success should not necessarily be judged by expecting every patch on the body to respond at the same rate.

Topical Corticosteroids: Still an Important Treatment

Despite newer therapies receiving considerable attention, topical corticosteroids remain an established treatment for vitiligo.

Their role is primarily anti-inflammatory. By suppressing immune activity in the affected skin, topical corticosteroids can help create an environment in which repigmentation may occur. Potent or very potent topical corticosteroids are included as first-line options for appropriate patients with stable vitiligo in published consensus recommendations.

However, potency, location, duration of treatment, and patient age matter. Prolonged or inappropriate corticosteroid use can produce adverse effects such as skin thinning, which is why dermatologists may use intermittent schedules, limit duration, or choose another medication for areas where long-term corticosteroid exposure is less desirable.

The medication that works well on the trunk, for example, may not be the medication a dermatologist wants someone applying around the eyes for months.

Tacrolimus and Pimecrolimus: Another Way to Control Local Inflammation

Topical calcineurin inhibitors such as tacrolimus and pimecrolimus suppress inflammatory signaling without causing the skin atrophy associated with topical corticosteroids.

That makes them particularly useful in areas such as the face, neck, skin folds, and other locations where prolonged corticosteroid use may be less desirable. Consensus recommendations specifically support topical calcineurin inhibitors as alternatives to corticosteroids for certain sensitive areas.

These medications were not originally developed specifically for vitiligo, but they have become established tools in its management.

And they illustrate something important about dermatology treatment: a medication does not necessarily need to have been created for a disease to have a clinically supported role in treating it.

Where JAK Inhibitors Enter the Picture

One of the more interesting developments in vitiligo treatment has come from a better understanding of the JAK-STAT pathway.

Janus kinase, or JAK, inhibitors interfere with intracellular signaling involved in immune and inflammatory responses. Because IFN-γ/JAK signaling appears to play an important role in the immune attack against melanocytes, researchers have investigated whether interrupting this pathway can help control vitiligo and facilitate repigmentation.

Ruxolitinib cream (Opzelura) is currently the only FDA-approved topical JAK inhibitor for vitiligo, cleared in 2022 for nonsegmental vitiligo in patients 12 and older based on the Phase 3 TRuE-V trials, which enrolled more than 600 patients. Those studies found that 29.9% of patients treated with ruxolitinib achieved at least a 75% improvement in the Facial Vitiligo Area Scoring Index (F-VASI75) at 24 weeks, compared with 7.5% and 12.9% of patients receiving vehicle cream in the respective trials. Improvement continued in some patients with longer treatment.

Tofacitinib is a different JAK inhibitor that has also been studied in both oral and topical forms for vitiligo, though it is not FDA-approved for this use — topical tofacitinib for vitiligo is an off-label, compounded treatment.

The evidence for tofacitinib is developing but promising. A randomized investigator-blinded trial published in 2025 compared topical tofacitinib 2% ointment with tacrolimus 0.1% ointment, each applied twice daily for 16 weeks to symmetrical patches in patients with localized nonsegmental vitiligo. Treatment success was achieved in 47% of tofacitinib-treated patches compared with 37% of tacrolimus-treated patches, although the difference was not statistically significant. More than 80% repigmentation occurred in 33% and 20% of patches, respectively. Facial lesions responded better than lesions on the trunk or acral areas.

Those results are encouraging, but they should be interpreted appropriately. The trial included only 30 patients, and larger studies are still needed to establish where topical tofacitinib ultimately fits within vitiligo treatment relative to approved options like ruxolitinib.

A recent systematic review similarly concluded that tofacitinib is promising but emphasized that much of the existing evidence comes from relatively small studies, case reports, case series, and heterogeneous treatment protocols.

In other words, promising does not mean proven for everyone. For patients weighing options, that means understanding both what is FDA-approved and what is available off-label as a compounded formulation — and discussing with a dermatologist which fits their disease pattern, prior treatment history, and preferences.

Light Can Be Part of the Treatment, Too

Medication is only part of the vitiligo treatment landscape.

Narrowband ultraviolet B (NB-UVB) phototherapy is an established treatment, particularly when vitiligo involves larger areas of the body. Targeted light or laser therapy may be considered when treatment needs to focus on more localized areas.

Phototherapy isn't simply a cosmetic tanning strategy. UV exposure is delivered in controlled therapeutic doses according to a treatment protocol.

It may also be combined with topical medication. Combination therapy can be more effective in certain circumstances than topical treatment alone, and there is particular scientific interest in combining therapies that suppress the immune process with light exposure that supports repigmentation.

That interaction may be especially relevant to JAK inhibition. Research involving tofacitinib has suggested that controlling immune signaling may not always be enough by itself to produce maximal repigmentation and that light exposure can play an important complementary role. Clinical studies have investigated tofacitinib alongside NB-UVB, although the evidence remains considerably less mature than it is for established phototherapy approaches.

Stopping Vitiligo and Repigmenting Vitiligo Are Not Exactly the Same Goal

This distinction is easy to miss.

Imagine someone who has developed several new areas of vitiligo over the past three months. If treatment prevents additional patches from appearing, that represents meaningful disease control even if the existing white patches have not yet completely repigmented.

Now consider someone whose vitiligo has been stable for years. Preventing new patches is less visible as a treatment goal because the disease is already inactive. For that patient, repigmentation may be the primary objective.

Dermatologists therefore evaluate more than how much color has returned. They may also consider whether existing patches have stopped enlarging and whether new lesions are still developing.

Repigmentation itself is usually gradual. Hair follicles can serve as important reservoirs for melanocytes, and returning pigment may initially appear as small islands around follicles before gradually expanding.

Treatment often requires patience measured in months rather than days or weeks.

Oral Treatment May Be Considered in Active Disease

When vitiligo is spreading rapidly, treatment may sometimes need to address disease activity more broadly rather than treating individual patches alone.

Systemic corticosteroids, including carefully designed oral regimens, have historically been used in selected patients to help stabilize rapidly progressive vitiligo. These are not routine treatments for every patient with vitiligo, and systemic corticosteroids carry important risks that must be weighed against potential benefit.

Systemic JAK inhibition is also being investigated. A randomized controlled trial published in 2025 compared oral tofacitinib 5 mg twice daily with dexamethasone oral mini-pulse therapy in adults with active nonsegmental vitiligo. The study found comparable stabilization at 24 weeks, with some later outcomes favoring tofacitinib, but it was a relatively small, single-center trial.

That does not establish oral tofacitinib as routine therapy for vitiligo. Systemic JAK inhibitors have substantially different safety considerations from topical treatment and require appropriate patient selection and monitoring.

For a patient reading about JAK inhibitors online, the distinction between topical and systemic therapy is therefore extremely important.

Repigmentation Is Possible, but Maintenance Matters

Even successful treatment does not necessarily mean vitiligo is permanently gone.

Vitiligo is a chronic disease, and pigmentation restored through treatment can sometimes be lost again. Maintenance therapy may therefore be considered after successful repigmentation, depending on the individual patient's disease and treatment response.

This is another reason dermatologists tend to think about vitiligo management as a longer-term process rather than a single prescription.

There are really several questions being asked at once:

Is the disease still active? Can we slow or stop progression? Which areas are most likely to repigment? Which treatment offers an appropriate balance of benefit and risk? And once pigmentation returns, how do we help maintain it?

The answers can change over time.

How Telederm Can Help

Vitiligo treatment has become increasingly individualized as researchers learn more about the immune pathways involved in pigment loss, and patients now have more options to weigh than ever — including FDA-approved therapies and off-label compounded formulations, each with a different evidence base and route to access.

Through Telederm, a board-certified dermatologist can review photographs, the distribution and progression of pigment changes, medical history, previous therapies, and other relevant factors to determine whether treatment may be appropriate. Depending on the individual patient, treatment may involve established topical therapies or other patient-specific options.

That decision belongs in a conversation between the patient and dermatologist.

The Bottom Line

Vitiligo is not simply a loss of skin color. It is a complex disease involving melanocytes, immune signaling, genetics, and other biological factors that researchers are continuing to understand.

Treatment is not just about choosing a medication from a list. Whether vitiligo is active or stable, where it appears, how extensive it is, and how the individual has responded to previous therapy can all influence the treatment plan.

Vitiligo may be visible on the surface, but effective treatment starts with understanding what is happening beneath it.

This content is for informational purposes only and is not a substitute for professional medical advice. Consult a licensed healthcare provider for diagnosis and treatment.

Treatment decisions, including any compounded medications, are made by the prescribing clinician based on individual evaluation. Compounded medications are not FDA-approved and have not been independently evaluated by the FDA for safety or efficacy.